Key Findings from the monarchE Trial

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the monarchE trial, which evaluated abemaciclib plus endocrine therapy for HR+, HER2 negative, node positive, high-risk early breast cancer.

Related Keywords

Stephanie Graff , , Treatment Approach , Breast Cancer , Rachel Layman , Early Breast Cancer , Hr , Ther2 , High Risk , Oncology , Endocrine Cdk4 6 Inhibitors , Recurrence , Monarche , Adjuvant , Grade , Abemaciclib , Tamoxifen ,